Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 30%
Sell 0%
Strong Sell 10%

Bulls say

Solventum is expected to continue its strong performance with organic growth in all segments and plans for offensive M&A, share repurchases, and debt repayment. The company is facing risks such as competition and institutional selling from its majority owner, but is expected to see positive changes in reimbursement and valuation. Overall, SOLV has a positive outlook with a Buy rating and projected annual top line growth of 4%.

Bears say

Solventum is a healthcare company with a diversified portfolio of products and solutions, but its most profitable segment, MedSurg, faces potential challenges such as decreasing healthcare spending and increased competition. Additionally, the company has a high level of debt and its margins have not yet reached the targets set at the company's Analyst Day in FY25, raising concerns about the effectiveness of its cost-cutting measures. Furthermore, post-spin separation activities from parent company 3M and potential stock dilution from secondary offerings could also impact Solventum's stock performance in the near-term.

Solventum Corporation (SOLV) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 30% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 10 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.